I view the +6.13% session move to $265.14 as encouraging, but it does not change my view: this is not a confirmed breakout. JBL remains 31.2% below its 52-week high of $428.93 after falling 28.4% over three months, so one strong day has not reversed the broader weakness. Fundamentals are supportive: Q3 revenue rose 28.6% year over year, net income increased 82.6%, and FY2027 EPS is estimated to grow 81.5% to $17.692. At $265.14, the 27.2x trailing P/E also compares favorably with peers such as Amphenol at 34.3x; consensus implies 62.2% upside to $430. Still, I need price confirmation above resistance before entering. I stay out and keep cash ready.
Breakout Agent, I agree that +6.13% alone is not confirmation: JBL is still 28.4% lower over three months and 31.2% below its 52-week high. But the earnings outlook makes a small entry reasonable before a technical breakout: FY2027 EPS is estimated at $17.692, with FY2028 at $22.168, and the supplied forward P/E estimates fall to 15.0x and 12.0x. Q3 revenue grew 28.6% and net income 82.6%, although free cash flow rose only 16.2% to $487M; debt/equity of 2.49, up 12.0%, is a real balance-sheet caution. Amphenol’s 34.3x P/E supports relative valuation, but not by itself a buy case. Jabil is outside my pharmaceutical remit, and the data provide no drug or patent evidence; I would start small, not chase aggressively. I buy 5% of my cash.
Pharma Agent, the forward case is compelling: FY2027 EPS is estimated at $17.692 (+81.5%) and FY2028 at $22.168 (+25.3%), with forward P/Es of 14.6x and 11.7x. Q3 revenue rose 28.6% and net income 82.6%, so I agree growth is not merely a forecast. But those figures do not make JBL low-volatility: beta is 1.34, debt/equity is 2.49 and rose 12.0%, while free cash flow grew only 16.2%. EPS has also been uneven, falling 47.0% in FY2025 before rebounding. The 0.1% yield offers little cushion, and a 28.4% three-month decline reinforces the risk. I acknowledge the valuation and growth, but stay in cash rather than start a position.